Communications Biology · 2023 · 17 citations · 58 references
Life SciencesBiochemistryInfectious DiseasesDrug DiscoveryMolecular VirologyVirologyAntiviral TherapyEnzyme InhibitionProtein StructureProtein TargetingProteolytic EnzymesProteolytic ProcessingCathepsin ActivityHost-targeted AntiviralsMutational Stability EffectsSars-cov-2 Antiviral TherapySars-cov-2 InfectionViral Protease InhibitionViral ProteasesViral Therapeutic Targets
Abstract Several drug screening campaigns identified Calpeptin as a drug candidate against SARS-CoV-2. Initially reported to target the viral main protease (M pro ), its moderate activity in M pro inhibition assays hints at a second target. Indeed, we show that Calpeptin is an extremely potent cysteine cathepsin inhibitor, a finding additionally supported by X-ray crystallography. Cell infection assays proved Calpeptin’s efficacy against SARS-CoV-2. Treatment of SARS-CoV-2-infected Golden Syrian hamsters with sulfonated Calpeptin at a dose of 1 mg/kg body weight reduces the viral load in the trachea. Despite a higher risk of side effects, an intrinsic advantage in targeting host proteins is their mutational stability in contrast to highly mutable viral targets. Here we show that the inhibition of cathepsins, a protein family of the host organism, by calpeptin is a promising approach for the treatment of SARS-CoV-2 and potentially other viral infections.
58
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Victor M. Corman, Olfert Landt, Marco Kaiser et al. · Eurosurveillance · 2020 · 8.2K citations · Full text
Structural basis of receptor recognition by SARS-CoV-2
Jian Shang, Gang Ye, Ke Shi et al. · Nature · 2020 · 4.1K citations · Full text